Skip to main content
. 2015 Sep 1;212(Suppl 2):S425–S434. doi: 10.1093/infdis/jiv223

Figure 5.

Figure 5.

MBX2254 and MBX2270 inhibit Ebola virus (EBOV) glycoprotein (GP)/Niemann-Pick C1 (NPC1) domain C interaction. A, Effects of MBX2254 and MBX2270 on EBOV GP/NPC1-domain C interaction. The inhibitory effect of compounds MBX2254 and MBX2270 on EBOV GP/NPC1-domain C interaction was investigated in an AlphaLISA format, as described in “Methods” section. Dose-response curves for MBX2254 and MBX2270 are shown. Compound 3.47, which is known to inhibit the EBOV-GP/NPC1-domain C interaction, was used as a positive control. Three independent experiments were performed to determine the effect of compounds. B, MBX2254 and MBX2270 inhibit EBOV-GP–mediated infection in an NPC1-dependent manner. Parental wild-type (WT) Chinese hamster ovary (CHO) cells and CHO cells stably overexpressing NPC1 were pretreated with the indicated concentration of inhibitor for 1 hour at 37°C and then infected with rVSV-GPΔ for 18 hours in the continued presence of inhibitor. Each concentration of inhibitor was tested in duplicate. Infection values were normalized to dimethyl sulfoxide–treated samples and averaged across experiments.